CA2350685A1 - Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique - Google Patents
Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique Download PDFInfo
- Publication number
- CA2350685A1 CA2350685A1 CA002350685A CA2350685A CA2350685A1 CA 2350685 A1 CA2350685 A1 CA 2350685A1 CA 002350685 A CA002350685 A CA 002350685A CA 2350685 A CA2350685 A CA 2350685A CA 2350685 A1 CA2350685 A1 CA 2350685A1
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- composition
- ethylhexyl
- matrix
- aqueous solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 148
- 239000011159 matrix material Substances 0.000 title claims abstract description 56
- 230000002500 effect on skin Effects 0.000 title claims abstract description 31
- 239000002537 cosmetic Substances 0.000 title claims description 30
- 238000001035 drying Methods 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- 239000013543 active substance Substances 0.000 claims description 57
- 239000001856 Ethyl cellulose Substances 0.000 claims description 33
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 33
- 229920001249 ethyl cellulose Polymers 0.000 claims description 33
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 33
- 229940124532 absorption promoter Drugs 0.000 claims description 26
- -1 aliphatic fatty acid ester Chemical class 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- 239000003125 aqueous solvent Substances 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 17
- 229920002678 cellulose Polymers 0.000 claims description 16
- 239000001913 cellulose Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000001704 evaporation Methods 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 14
- OUCGJMIVSYHBEC-UHFFFAOYSA-N 2-ethylhexyl 2-ethylhexanoate Chemical compound CCCCC(CC)COC(=O)C(CC)CCCC OUCGJMIVSYHBEC-UHFFFAOYSA-N 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 230000008020 evaporation Effects 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 229940044551 receptor antagonist Drugs 0.000 claims description 8
- 101710151321 Melanostatin Proteins 0.000 claims description 7
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229940074052 glyceryl isostearate Drugs 0.000 claims description 4
- 229940100463 hexyl laurate Drugs 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 239000001273 butane Substances 0.000 claims description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- SEWAAPWEWOCMKK-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCOCCOCC SEWAAPWEWOCMKK-UHFFFAOYSA-N 0.000 claims 2
- DDGZCTKMHAYRKN-UHFFFAOYSA-N 2-ethylhexyl 12-acetyloxyoctadecanoate Chemical compound CCCCCCC(OC(C)=O)CCCCCCCCCCC(=O)OCC(CC)CCCC DDGZCTKMHAYRKN-UHFFFAOYSA-N 0.000 claims 2
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 claims 2
- QIVJGFWGDVLWQP-UHFFFAOYSA-N 2-ethylhexyl undec-10-enoate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC=C QIVJGFWGDVLWQP-UHFFFAOYSA-N 0.000 claims 2
- ZQXRINMCMHCYBD-UHFFFAOYSA-N 4-(2-ethylhexoxy)-4-oxobutanoic acid Chemical compound CCCCC(CC)COC(=O)CCC(O)=O ZQXRINMCMHCYBD-UHFFFAOYSA-N 0.000 claims 2
- 241000194108 Bacillus licheniformis Species 0.000 claims 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 claims 2
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 claims 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 11
- 210000003491 skin Anatomy 0.000 description 40
- 229960004667 ethyl cellulose Drugs 0.000 description 24
- 238000009472 formulation Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 13
- 239000007789 gas Substances 0.000 description 12
- 210000000689 upper leg Anatomy 0.000 description 12
- 238000009792 diffusion process Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 5
- 208000035484 Cellulite Diseases 0.000 description 5
- 102400000064 Neuropeptide Y Human genes 0.000 description 5
- 206010049752 Peau d'orange Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036232 cellulite Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229940100554 isononyl isononanoate Drugs 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241001484259 Lacuna Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- DJNTZVRUYMHBTD-UHFFFAOYSA-N Octyl octanoate Chemical compound CCCCCCCCOC(=O)CCCCCCC DJNTZVRUYMHBTD-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 150000001298 alcohols Chemical group 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- GCHBANQNCWIASI-UHFFFAOYSA-N C(=O)=O.CC(C)C.CCC.CCCC Chemical compound C(=O)=O.CC(C)C.CCC.CCCC GCHBANQNCWIASI-UHFFFAOYSA-N 0.000 description 1
- DPCRCMPOKSFLEF-UHFFFAOYSA-N C(C)(=O)OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.C(CCC(=O)O)(=O)OCC(CCCC)CC.C(CCCCCCCCC=C)(=O)OCC(CCCC)CC.C(CCCCCCC)C(CO)CCCCCCCC Chemical compound C(C)(=O)OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.C(CCC(=O)O)(=O)OCC(CCCC)CC.C(CCCCCCCCC=C)(=O)OCC(CCCC)CC.C(CCCCCCC)C(CO)CCCCCCCC DPCRCMPOKSFLEF-UHFFFAOYSA-N 0.000 description 1
- JFDDCTNNCXGWIR-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)(=O)OC(C)C.C(CCCCCCCCCCCCC)(=O)OCCOCCOCC.C(CCCCCCCCCCCCC)(=O)OC(C)C.C(C)C(COC(C(CCCC)CC)=O)CCCC Chemical compound C(CCCCCCCCCCCCCCC)(=O)OC(C)C.C(CCCCCCCCCCCCC)(=O)OCCOCCOCC.C(CCCCCCCCCCCCC)(=O)OC(C)C.C(C)C(COC(C(CCCC)CC)=O)CCCC JFDDCTNNCXGWIR-UHFFFAOYSA-N 0.000 description 1
- UTVODUXIIFTYJM-UHFFFAOYSA-N CCCC.CCCCC.[N]=O.CCC(C)C.[N] Chemical compound CCCC.CCCCC.[N]=O.CCC(C)C.[N] UTVODUXIIFTYJM-UHFFFAOYSA-N 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229940119154 Neuropeptide Y receptor antagonist Drugs 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006341 curative response Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention cencerne une nouvelle composition pour administration dermique d'une substance ou d'un principe actif. Plus précisément, l'invention concerne une composition amincissante pour administration dermique, capable de former un film souple après séchage sur la peau ainsi qu'une matrice utilisable dans une telle composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9816422A FR2787712B1 (fr) | 1998-12-24 | 1998-12-24 | Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique |
| FR98/16422 | 1998-12-24 | ||
| PCT/FR1999/003051 WO2000038658A1 (fr) | 1998-12-24 | 1999-12-08 | Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2350685A1 true CA2350685A1 (fr) | 2000-07-06 |
Family
ID=9534488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002350685A Abandoned CA2350685A1 (fr) | 1998-12-24 | 1999-12-08 | Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1140040A1 (fr) |
| JP (1) | JP2002533383A (fr) |
| KR (1) | KR20010089699A (fr) |
| CN (1) | CN1331587A (fr) |
| AU (1) | AU4520500A (fr) |
| BR (1) | BR9916814A (fr) |
| CA (1) | CA2350685A1 (fr) |
| FR (1) | FR2787712B1 (fr) |
| HU (1) | HUP0200095A2 (fr) |
| IL (1) | IL143144A0 (fr) |
| NO (1) | NO20013117L (fr) |
| PL (1) | PL365376A1 (fr) |
| TR (1) | TR200101569T2 (fr) |
| WO (1) | WO2000038658A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2754709B1 (fr) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| GB0518769D0 (en) * | 2005-09-14 | 2005-10-19 | Medpharm Ltd | Topical formulations |
| JP4679350B2 (ja) * | 2005-11-24 | 2011-04-27 | 株式会社資生堂 | 水中油型乳化皮膚化粧料 |
| EP2153836A1 (fr) * | 2008-08-04 | 2010-02-17 | Polichem S.A. | Formules liquides formant un film pour libération de médicament dans les cheveux et sur le cuir chevelu |
| KR101163862B1 (ko) * | 2010-03-23 | 2012-07-09 | (주)아모레퍼시픽 | 수중유형 나노 에멀젼 조성물 및 이의 제조방법 |
| ITCA20120004A1 (it) * | 2012-03-30 | 2012-06-29 | Abdelkrim Harchi | Unico reattivo disidratante e diafanizzante per istologia e citologia non nocivo e non tossico, biodegradabile 88%, a bassa volatilita' |
| CN115335024A (zh) * | 2020-03-02 | 2022-11-11 | Elc管理有限责任公司 | 使用纳米纤维用于修复皮肤的方法 |
| KR20220148884A (ko) * | 2020-03-02 | 2022-11-07 | 이엘씨 매니지먼트 엘엘씨 | 화장제의 전달, 조성물 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289900A1 (fr) * | 1987-04-30 | 1988-11-09 | Abbott Laboratories | Compositions antibactériennes topiques |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| FR2754709B1 (fr) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
-
1998
- 1998-12-24 FR FR9816422A patent/FR2787712B1/fr not_active Expired - Fee Related
-
1999
- 1999-12-08 KR KR1020017008101A patent/KR20010089699A/ko not_active Application Discontinuation
- 1999-12-08 CN CN99814967A patent/CN1331587A/zh active Pending
- 1999-12-08 BR BR9916814-6A patent/BR9916814A/pt not_active Application Discontinuation
- 1999-12-08 AU AU45205/00A patent/AU4520500A/en not_active Abandoned
- 1999-12-08 HU HU0200095A patent/HUP0200095A2/hu unknown
- 1999-12-08 TR TR2001/01569T patent/TR200101569T2/xx unknown
- 1999-12-08 CA CA002350685A patent/CA2350685A1/fr not_active Abandoned
- 1999-12-08 JP JP2000590612A patent/JP2002533383A/ja not_active Withdrawn
- 1999-12-08 PL PL99365376A patent/PL365376A1/xx not_active Application Discontinuation
- 1999-12-08 EP EP99973534A patent/EP1140040A1/fr not_active Withdrawn
- 1999-12-08 WO PCT/FR1999/003051 patent/WO2000038658A1/fr not_active Application Discontinuation
- 1999-12-08 IL IL14314499A patent/IL143144A0/xx unknown
-
2001
- 2001-06-21 NO NO20013117A patent/NO20013117L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2787712A1 (fr) | 2000-06-30 |
| EP1140040A1 (fr) | 2001-10-10 |
| AU4520500A (en) | 2000-07-31 |
| NO20013117L (no) | 2001-08-24 |
| WO2000038658A1 (fr) | 2000-07-06 |
| CN1331587A (zh) | 2002-01-16 |
| BR9916814A (pt) | 2001-10-16 |
| PL365376A1 (en) | 2005-01-10 |
| IL143144A0 (en) | 2002-04-21 |
| NO20013117D0 (no) | 2001-06-21 |
| KR20010089699A (ko) | 2001-10-08 |
| TR200101569T2 (tr) | 2001-10-22 |
| FR2787712B1 (fr) | 2002-08-30 |
| HUP0200095A2 (hu) | 2002-05-29 |
| JP2002533383A (ja) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080019927A1 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
| US6010716A (en) | Pharmaceutical composition for transdermal administration | |
| TWI225407B (en) | An acidified composition for topical treatment of nail and skin conditions | |
| US8741332B2 (en) | Compositions and methods for dermally treating neuropathic pain | |
| AU2006332066B2 (en) | Use of film-forming hair-care polymers from the group of polyurethanes and pharmaceutical preparations and plasters containing said polymers | |
| US20030152611A1 (en) | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | |
| US20070196293A1 (en) | Compositions and methods for treating photo damaged skin | |
| KR101709489B1 (ko) | 레티노이드를 포함하는 조성물 및 피부 상태를 처리하는 방법 | |
| US20060088497A1 (en) | Topical skin care composition | |
| Gennari et al. | Medicated foams and film forming dosage forms as tools to improve the thermodynamic activity of drugs to be administered through the skin | |
| CA2350685A1 (fr) | Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique | |
| KR20230097052A (ko) | 개선된 효능을 갖는 백반증 병변의 치료 방법 | |
| EP4285931A1 (fr) | Composition pour application externe | |
| KR20180130178A (ko) | 리포좀 및 이를 포함하는 화장료 조성물 | |
| MXPA01006463A (en) | Spray-type cosmetic composition and matrix used in said composition for dermal administration | |
| Al-Jarsha et al. | A Review on Film Forming Drug Delivery Systems | |
| KR102566124B1 (ko) | 초음파 미용기기용 겔 화장료 조성물 및 이의 제조방법 | |
| EP3692981B1 (fr) | Composition topique destinée à être utilisée dans le traitement du psoriasis | |
| JP2003335658A (ja) | 敏感肌用の化粧料 | |
| MX2007013912A (es) | Administracion de baja dosis de una composicion topica. | |
| JP2003055185A (ja) | 皮膚外用剤 | |
| WO2022098320A1 (fr) | Compositions pharmaceutiques topiques contenant du minoxidil et des excipients appropriés | |
| Sholikhah et al. | Comparative study of nanoemulsion gel and essential oil from cassumunar ginger (Zingiber cassumunar Roxb.) as a topical antiobesity: In vivo study in mice | |
| WO2024098062A2 (fr) | Oxybutynine topique pour bouffées de chaleur | |
| Bagul et al. | Emulgel-A Novel Advance for Skin Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |